FSD Pharma Inc. (HUGE.CN)
| Previous Close | 1.6100 |
| Open | 0.0000 |
| Bid | 1.6200 x 0 |
| Ask | 1.6500 x 0 |
| Day's Range | 0.0000 - 0.0000 |
| 52 Week Range | |
| Volume | |
| Avg. Volume | 31,600 |
| Market Cap | 63.246M |
| Beta (5Y Monthly) | 1.04 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9600 |
| Earnings Date | Nov 09, 2023 - Nov 13, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireInvestmentPitch Media Video Discusses FSD Pharma’s Continued Development of its Exciting New Rapid Detox Drink UNBUZZD™, with Video Comments from Kevin Harrington
VANCOUVER, British Columbia, Sept. 22, 2023 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biotechnology company building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, continues with the development of its exciting new rapid detox drink UNBUZZD™. Today, we’re following up on our August 2nd feature video in which we discussed UNBUZZD™, a proprietary formulation of natural
ACCESSWIREFSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis; The Report Shows Compound to be Safe and Well Tolerated
FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, today announced that an interim report has been received for the first-in-human ("FIH") single ascending dose Phase I clinical trial evaluating the Company's novel drug candidate Lucid-21-302
- ACCESSWIRE
FSD Pharma Announces Analyst Coverage Initiated by Singular Research
FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, today announced that Singular Research has initiated analyst coverage on FSD Pharma.
